GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Operating Margin %

Microba Life Sciences (ASX:MAP) Operating Margin % : -467.64% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Microba Life Sciences's Operating Income for the six months ended in Dec. 2023 was A$-15.31 Mil. Microba Life Sciences's Revenue for the six months ended in Dec. 2023 was A$3.27 Mil. Therefore, Microba Life Sciences's Operating Margin % for the quarter that ended in Dec. 2023 was -467.64%.

The historical rank and industry rank for Microba Life Sciences's Operating Margin % or its related term are showing as below:

ASX:MAP' s Operating Margin % Range Over the Past 10 Years
Min: -406.04   Med: -360.14   Max: -347.02
Current: -406.04


ASX:MAP's Operating Margin % is ranked worse than
86.88% of 221 companies
in the Medical Diagnostics & Research industry
Industry Median: -4.39 vs ASX:MAP: -406.04

Microba Life Sciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Microba Life Sciences's Operating Income for the six months ended in Dec. 2023 was A$-15.31 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was A$-26.56 Mil.


Microba Life Sciences Operating Margin % Historical Data

The historical data trend for Microba Life Sciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Operating Margin % Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23
Operating Margin %
-347.02 -373.25

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % - - -417.15 -344.36 -467.64

Competitive Comparison of Microba Life Sciences's Operating Margin %

For the Diagnostics & Research subindustry, Microba Life Sciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microba Life Sciences's Operating Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's Operating Margin % falls into.



Microba Life Sciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Microba Life Sciences's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-20.23 / 5.42
=-373.25 %

Microba Life Sciences's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-15.306 / 3.273
=-467.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microba Life Sciences  (ASX:MAP) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Microba Life Sciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Microba Life Sciences (ASX:MAP) Business Description

Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines